InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
10
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by Bazemore Todd, Chief Operating Officer. Director active across 3 companies, notably Kala Pharmaceuticals, Inc.. In total, 16 disclosures have been published. Split: 0 buy · 10 sells. Total volume traded: €110k. Activity tracked since 28 June 2021. The latest transaction was filed on 6 January 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations16 total
10,100 shares0Common StockSEC:0001415889-25-001062:0
4,653 shares@ US$4.7563.8% of flowCommon StockSEC:0001415889-24-018377:0
2,093 shares@ US$6.0936.2% of flowCommon StockSEC:0001415889-24-015226:0
6,500 shares0Common StockSEC:0001415889-24-000766:0
48,698 shares0Common StockSEC:0001415889-23-010283:0
21,158 sharesCommon StockSEC:0001415889-23-009134:0
12,800 shares0Common StockSEC:0001415889-23-000637:0
214 shares@ US$6.511.8% of flowCommon StockSEC:0001415889-22-010881:0
3,092 shares@ US$0.370.0070% mcap1.4% of flowCommon StockSEC:0001415889-22-007060:0
3,454 shares@ US$1.305.1% of flowCommon StockSEC:0001415889-22-000403
3,454 shares@ US$1.300.026% mcap5.2% of flowCommon StockSEC:0001415889-22-000403:0
12,544 shares@ US$1.800.13% mcap25.6% of flowCommon StockSEC:0001415889-21-005011:0
12,544 shares@ US$1.8025.1% of flowCommon StockSEC:0001415889-21-005011
2,911 shares@ US$5.7718.2% of flowCommon StockSEC:0001415889-21-003257
2,911 shares@ US$5.770.091% mcap18.5% of flowCommon StockSEC:0001415889-21-003257:0
13,750 sharesCommon StockSEC:0000908662-16-000427:0
16 of 16 declarations
About Bazemore Todd
Todd Bazemore is the Chief Operating Officer at Kala Pharmaceuticals, Inc. He is responsible for managing the company's operations, contributing to overall efficiency and performance. His role is essential for the operational strategy of Kala Pharmaceuticals, Inc.
